1870-LB: Evaluating Remission of Type 2 Diabetes Using a Metabolic Intervention Including Fixed-Ratio Insulin Degludec and Liraglutide—A Randomized Controlled Trial

Introduction p 0.0001), and lost more weight (3.3 ± 4.4% vs 1.9 ± 3.0%; p=0.02). There was a lower hazard of diabetes relapse overall in the intervention group compared to controls (HR 0.63; 95%CI 0.45, 0.88; p=0.007) but this was not sustained over time. Remission rates in the intervention group were not significantly higher at 12 weeks (17.7% vs 12.5%; RR 1.42, 95%CI 0.67, 3.00; p=0.36) or 52 weeks (6.3% vs 3.8%; RR 1.69, 95%CI 0.42, 6.82) following the intervention period. Conclusion: An intensive remission-induction intervention including fixed-ratio insulin degludec/liraglutide reduced the risk of type 2 diabetes relapse without sustained remission. Disclosure Z. Punthakee: Advisory Panel; Dexcom, Inc., Sanofi. Research Support; Novo Nordisk. Advisory Panel; Eli Lilly and Company. S. Hall: None. N. McInnes: Other Relationship; Sanofi. D. Sherifali: None. K. Tsiplova: None. M. Ghosh: Advisory Panel; Viatris Inc. S.B. Harris: Consultant; Abbott. Research Support; Boehringer-Ingelheim. Consultant; Dexcom, Inc. Advisory Panel; Eli Lilly and Company. Consultant; Eli Lilly and Company, Novo Nordisk, Sanofi. Research Support; Novartis AG. Consultant; Bayer Inc. H.A. Lochnan: Research Support; Novo Nordisk. Advisory Panel; Ipsen. Research Support; Spruce Biosciences. T.P.P. Ransom: Advisory Panel; Abbott. Speaker's Bureau; Abbott. Advisory Panel; Aegerion Pharmaceuticals. Speaker's Bureau; Amgen Inc. Other Relationship; Boehringer-Ingelheim, Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company, GlaxoSmithKline plc. Other Relationship; Medtronic. Advisory Panel; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Other Relationship; Novo Nordisk, Sanofi. R.J. Sigal: Research Support; Lexicon Pharmaceuticals, Inc., Bayer Inc., Novo Nordisk. T. Spaic: Research Support; Novo Nordisk Canada Inc., Lilly Diabetes. Advisory Panel; Sanofi, Dexcom, Inc. Research Support; Tandem Diabetes Care, Inc. H.C. Gerstein: Advisory Panel; Sanofi. Research Support; Sanofi. Advisory Panel; Abbott, Eli Lilly and Company. Research Support; Eli Lilly and Company. Other Relationship; Eli Lilly and Company. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Other Relationship; Novo Nordisk, AstraZeneca. Research Support; Hanmi Pharm. Co., Ltd. Advisory Panel; Hanmi Pharm. Co., Ltd. Other Relationship; Zuellig Pharma Holdings Pte. Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Carbon Brand. Consultant; Boehringer-Ingelheim, Kowa Company, Ltd., Pfizer Inc., Shionogi & Co., Ltd. Funding Novo Nordisk